Home › Biocartis, Exploit Technologies Ink MDx Assay Development Deal

Biocartis, Exploit Technologies Ink MDx Assay Development Deal

Jul 10, 2017

NEW YORK (GenomeWeb) – Biocartis announced today that it has extended its partnership with Exploit Technologies (ETPL) — the commercialization arm of Singapore's Agency for Science, Technology, and Research — to develop molecular diagnostic assays, including one for breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
03
Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Featured Webinar

Clinical-Grade Exome Analysis for Complex and Unsolved Case Investigations

Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
12
Featured Webinar

Precision Metagenomics to Identify Patients at Risk for Invasive Infection

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.

What's Popular?

In Molecular Diagnostics

  1. BioMérieux Pneumonia Panels Get FDA 510(k) Clearance, CE Mark

  2. Natera Waits for ACOG Guidance on Average-Risk NIPT; Pushes Ahead in Oncology, Transplantation

    Premium

  3. Health Canada Approves Two BCR-ABL Tests

  4. LabCorp, Sysmex, Diazyme, and Others Receive FDA Clearances for Assays, Diagnostic Systems in October

  5. Guardant Health, Core Diagnostics Team Up to Offer Liquid Biopsy in India

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.